C Zhang1, R Zhang2. 1. Division of Geriatric and Palliative Medicine, School of Medicine, University of Michigan, Ann Arbor, MI, USA. 2. Center for Molecular Medicine and Genetics, and the Cardiovascular Research Institute, School of Medicine, Wayne State University, Detroit, MI, USA. Electronic address: rzhang@med.wayne.edu.
Abstract
AIM: Metformin, a first-line diabetes drug, delays the onset of type 2 diabetes in the prediabetic population; however, in prediabetic patients, differences in glycaemic response to metformin among racial groups are unknown. We aimed to compare glucose-lowering effects of metformin between Whites and African Americans (AAs). METHODS: We performed a secondary analysis using data from the diabetes prevention program, a multi-center randomized clinical trial, in which all participants were prediabetic. The metformin group (582 Whites and 210 AAs) received 850 mg of metformin twice daily, and was followed for 3 years. RESULTS: We found that after 6 months on metformin, Whites had a drop of 3.89 ± 0.39 (mg/dL, mean ± SEM) in the fasting plasma glucose level, significantly less than that in African Americans (6.04 ± 0.72, P=0.006); at years 1 and 2, the differences were also significant. Consistently, the linear mixed model showed that, within 1 year of metformin treatment, the rate in reduction of glucose levels was more pronounced in AAs than in Whites (P=0.025 following adjustment for age and sex). CONCLUSIONS: Therefore, AAs have a better glycaemic response to metformin treatment than Whites in the prediabetic population.
RCT Entities:
AIM: Metformin, a first-line diabetes drug, delays the onset of type 2 diabetes in the prediabetic population; however, in prediabetic patients, differences in glycaemic response to metformin among racial groups are unknown. We aimed to compare glucose-lowering effects of metformin between Whites and African Americans (AAs). METHODS: We performed a secondary analysis using data from the diabetes prevention program, a multi-center randomized clinical trial, in which all participants were prediabetic. The metformin group (582 Whites and 210 AAs) received 850 mg of metformin twice daily, and was followed for 3 years. RESULTS: We found that after 6 months on metformin, Whites had a drop of 3.89 ± 0.39 (mg/dL, mean ± SEM) in the fasting plasma glucose level, significantly less than that in African Americans (6.04 ± 0.72, P=0.006); at years 1 and 2, the differences were also significant. Consistently, the linear mixed model showed that, within 1 year of metformin treatment, the rate in reduction of glucose levels was more pronounced in AAs than in Whites (P=0.025 following adjustment for age and sex). CONCLUSIONS: Therefore, AAs have a better glycaemic response to metformin treatment than Whites in the prediabetic population.
Authors: Jeffrey F Scherrer; John E Morley; Joanne Salas; James S Floyd; Susan A Farr; Sascha Dublin Journal: Ann Fam Med Date: 2019-07 Impact factor: 5.166
Authors: Lisa Scarton; Ara Jo; Zhigang Xie; LaToya J O'Neal; Juan M Munoz Pena; Thomas J George; Jiang Bian Journal: PLoS One Date: 2022-10-19 Impact factor: 3.752
Authors: Tannaz Moin; Julie A Schmittdiel; James H Flory; Jessica Yeh; Andrew J Karter; Lydia E Kruge; Dean Schillinger; Carol M Mangione; William H Herman; Elizabeth A Walker Journal: Am J Prev Med Date: 2018-08-17 Impact factor: 6.604